Positron Emission Tomography (PET) Study

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Radiation: 2-[18F]-F-A85380; Drug: AZD1446

Study type: Interventional

Funder types: Industry

Identifiers

NCT00886067

D1950C00004

EudraCT No. 2008-008390-55

Details and patient eligibility

About

The primary purpose is to study the occupancy at the α4β2 neuronal nicotinic receptor's (NNRs) and to determine the relation between plasma concentration of AZD1446 and the occupancy at α4β2 NNRs.

Enrollment: 11 patients

Sex: All

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Physically healthy volunteers
• Body weight between 50 to 100 kg and body mass index (BMI) between 19 and 30 kg/m2

Exclusion criteria

• History of any clinically significant disease or disorder
• History of severe allergy/hypersensitivity reactions
• Participation in a PET examination as part of a scientific study during the past twelve months

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

11 participants in 2 patient groups

2-[18F]-F-A85380

Experimental group

Description:

Single microdose

Treatment:

Radiation: 2-[18F]-F-A85380

AZD1446

Experimental group

Description:

Single oral administration

Treatment:

Drug: AZD1446